Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Intra-Cellular participates in a conference call with JPMorgan » 10:59
11/10/21
11/10
10:59
11/10/21
10:59
ITCI

Intra-Cellular

$43.25 /

-1.12 (-2.52%)

Conference call with CEO…

Conference call with CEO Mates will be held on November 10 at 11 am hosted by JPMorgan.Webcast Link

ShowHide Related Items >><<
ITCI Intra-Cellular
$43.25 /

-1.12 (-2.52%)

ITCI Intra-Cellular
$43.25 /

-1.12 (-2.52%)

10/19/21 RBC Capital
Intra-Cellular price target raised to $48 from $44 at RBC Capital
09/22/21 Needham
Intra-Cellular initiated with a Buy at Needham
09/20/21 Jefferies
Intra-Cellular price target raised to $70 from $55 at Jefferies
12/29/20 Cantor Fitzgerald
Intra-Cellular price target raised to $54 from $53 at Cantor Fitzgerald
ITCI Intra-Cellular
$43.25 /

-1.12 (-2.52%)

Earnings
Intra-Cellular reports Q3 EPS (95c), consensus (92c) » 07:38
11/09/21
11/09
07:38
11/09/21
07:38
ITCI

Intra-Cellular

$44.28 /

-0.36 (-0.81%)

Reports Q3 revenue…

Reports Q3 revenue $22.2M, consensus $22.12M. "We are excited about the progress we have made during the third quarter in the commercialization of CAPLYTA in schizophrenia and in the advancement of our development programs. In addition, our bipolar depression launch preparations are progressing well and we have substantially completed our sales force expansion," said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.

ShowHide Related Items >><<
ITCI Intra-Cellular
$44.28 /

-0.36 (-0.81%)

ITCI Intra-Cellular
$44.28 /

-0.36 (-0.81%)

10/19/21 RBC Capital
Intra-Cellular price target raised to $48 from $44 at RBC Capital
09/22/21 Needham
Intra-Cellular initiated with a Buy at Needham
09/20/21 Jefferies
Intra-Cellular price target raised to $70 from $55 at Jefferies
12/29/20 Cantor Fitzgerald
Intra-Cellular price target raised to $54 from $53 at Cantor Fitzgerald
ITCI Intra-Cellular
$44.28 /

-0.36 (-0.81%)

Over a month ago
Conference/Events
Intra-Cellular to hold a virtual investor event » 12:25
10/20/21
10/20
12:25
10/20/21
12:25
ITCI

Intra-Cellular

$41.83 /

-0.02 (-0.05%)

Virtual Event to feature…

Virtual Event to feature highlights of several of the Company's development pipeline including lumateperone, ITI-1284, PDE inhibitor platform and ITI-333 will be held on October 20 at 1 pm. Webcast Link

ShowHide Related Items >><<
ITCI Intra-Cellular
$41.83 /

-0.02 (-0.05%)

ITCI Intra-Cellular
$41.83 /

-0.02 (-0.05%)

10/19/21 RBC Capital
Intra-Cellular price target raised to $48 from $44 at RBC Capital
09/22/21 Needham
Intra-Cellular initiated with a Buy at Needham
09/20/21 Jefferies
Intra-Cellular price target raised to $70 from $55 at Jefferies
12/29/20 Cantor Fitzgerald
Intra-Cellular price target raised to $54 from $53 at Cantor Fitzgerald
ITCI Intra-Cellular
$41.83 /

-0.02 (-0.05%)

Conference/Events
Intra-Cellular to hold a virtual investor event » 04:55
10/20/21
10/20
04:55
10/20/21
04:55
ITCI

Intra-Cellular

$41.87 /

+0.2 (+0.48%)

Virtual Event to feature…

Virtual Event to feature highlights of several of the Company's development pipeline including lumateperone, ITI-1284, PDE inhibitor platform and ITI-333 will be held on October 20 at 1 pm. Webcast Link

ShowHide Related Items >><<
ITCI Intra-Cellular
$41.87 /

+0.2 (+0.48%)

ITCI Intra-Cellular
$41.87 /

+0.2 (+0.48%)

10/19/21 RBC Capital
Intra-Cellular price target raised to $48 from $44 at RBC Capital
09/22/21 Needham
Intra-Cellular initiated with a Buy at Needham
09/20/21 Jefferies
Intra-Cellular price target raised to $70 from $55 at Jefferies
12/29/20 Cantor Fitzgerald
Intra-Cellular price target raised to $54 from $53 at Cantor Fitzgerald
ITCI Intra-Cellular
$41.87 /

+0.2 (+0.48%)

Recommendations
Intra-Cellular price target raised to $48 from $44 at RBC Capital » 09:05
10/19/21
10/19
09:05
10/19/21
09:05
ITCI

Intra-Cellular

$41.67 /

+2.36 (+6.00%)

RBC Capital analyst Brian…

RBC Capital analyst Brian Abrahams raised the firm's price target on Intra-Cellular to $48 from $44 and keeps an Outperform rating on the shares. The stock has bounced back recently on improving recognition that the potential December bipolar label expansion and the waning COVID headwinds could "catalyze a 2022 sales inflection", the analyst tells investors in a research note. Abrahams adds that he anticipates increasing Caplyta enthusiasm as investors look beyond the upcoming quarters and appreciate longer-term indication expansion and its life cycle potential.

ShowHide Related Items >><<
ITCI Intra-Cellular
$41.67 /

+2.36 (+6.00%)

ITCI Intra-Cellular
$41.67 /

+2.36 (+6.00%)

09/22/21 Needham
Intra-Cellular initiated with a Buy at Needham
09/20/21 Jefferies
Intra-Cellular price target raised to $70 from $55 at Jefferies
12/29/20 Cantor Fitzgerald
Intra-Cellular price target raised to $54 from $53 at Cantor Fitzgerald
12/15/20
Fly Intel: Top five analyst initiations
ITCI Intra-Cellular
$41.67 /

+2.36 (+6.00%)

Hot Stocks
Intra-Cellular announces amended start time to October 20 virtual event » 08:16
10/18/21
10/18
08:16
10/18/21
08:16
ITCI

Intra-Cellular

$39.32 /

-0.03 (-0.08%)

Intra-Cellular Therapies…

Intra-Cellular Therapies announced the Company's Virtual Event featuring highlights of its development programs being held on Wednesday, October 20, 2021 will now begin at 1:00 p.m. ET. The virtual event will run from 1:00 p.m. ET - 4:00 p.m. ET.

ShowHide Related Items >><<
ITCI Intra-Cellular
$39.32 /

-0.03 (-0.08%)

ITCI Intra-Cellular
$39.32 /

-0.03 (-0.08%)

09/22/21 Needham
Intra-Cellular initiated with a Buy at Needham
09/20/21 Jefferies
Intra-Cellular price target raised to $70 from $55 at Jefferies
12/29/20 Cantor Fitzgerald
Intra-Cellular price target raised to $54 from $53 at Cantor Fitzgerald
12/15/20
Fly Intel: Top five analyst initiations
ITCI Intra-Cellular
$39.32 /

-0.03 (-0.08%)

Conference/Events
Jefferies specialty pharma analyst to hold analyst/industry conference call » 11:45
10/15/21
10/15
11:45
10/15/21
11:45
ABBV

AbbVie

$109.14 /

+0.18 (+0.17%)

, ITCI

Intra-Cellular

$39.55 /

+0.2 (+0.51%)

, ALKS

Alkermes

$32.12 /

+0.26 (+0.82%)

, KRTX

Karuna Therapeutics

$123.19 /

+0.515 (+0.42%)

, OTSKY

Otsuka

$21.31 /

+0.155 (+0.73%)

Specialty Pharma &…

Specialty Pharma & Healthcare Services Analyst Vane-Tempest, along with Dr. Robert Feder a psychiatrist in private practice in Manchester, NH, discuss antipsychotics on an Analyst/Industry conference call to be held on October 15 at 12 pm.

ShowHide Related Items >><<
OTSKY Otsuka
$21.31 /

+0.155 (+0.73%)

KRTX Karuna Therapeutics
$123.19 /

+0.515 (+0.42%)

ITCI Intra-Cellular
$39.55 /

+0.2 (+0.51%)

ALKS Alkermes
$32.12 /

+0.26 (+0.82%)

ABBV AbbVie
$109.14 /

+0.18 (+0.17%)

ABBV AbbVie
$109.14 /

+0.18 (+0.17%)

10/05/21 Piper Sandler
Biohaven Pharmaceutical price target raised to $156 from $140 at Piper Sandler
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/14/21 Barclays
Regenxbio price target raised to $82 from $79 at Barclays
09/13/21 Chardan
Regenxbio pact with AbbVie accelerates RGX-314 'value capture,' says Chardan
ITCI Intra-Cellular
$39.55 /

+0.2 (+0.51%)

09/22/21 Needham
Intra-Cellular initiated with a Buy at Needham
09/20/21 Jefferies
Intra-Cellular price target raised to $70 from $55 at Jefferies
12/29/20 Cantor Fitzgerald
Intra-Cellular price target raised to $54 from $53 at Cantor Fitzgerald
12/15/20
Fly Intel: Top five analyst initiations
ALKS Alkermes
$32.12 /

+0.26 (+0.82%)

10/06/21 Jefferies
Alkermes upgraded to Buy from Hold at Jefferies
09/27/21 BofA
Alkermes takeover thesis 'highly speculative,' says BofA
09/10/21 Mizuho
Alkermes price target raised to $36 from $33 at Mizuho
09/02/21
Fly Intel: Top five analyst downgrades
KRTX Karuna Therapeutics
$123.19 /

+0.515 (+0.42%)

09/30/21 JPMorgan
Karuna Therapeutics initiated with an Overweight at JPMorgan
08/30/21 Citi
Karuna Therapeutics initiated with a Buy at Citi
07/28/21
Fly Intel: Top five analyst initiations
07/28/21 Jefferies
Karuna Therapeutics initiated with a Buy at Jefferies
OTSKY Otsuka
$21.31 /

+0.155 (+0.73%)

07/14/21 Goldman Sachs
Otsuka downgraded to Sell from Neutral at Goldman Sachs
06/17/21 Daiwa
Otsuka upgraded to Outperform from Neutral at Daiwa
03/15/21 Daiwa
Otsuka downgraded to Neutral from Outperform at Daiwa
KRTX Karuna Therapeutics
$123.19 /

+0.515 (+0.42%)

ITCI Intra-Cellular
$39.55 /

+0.2 (+0.51%)

ALKS Alkermes
$32.12 /

+0.26 (+0.82%)

ABBV AbbVie
$109.14 /

+0.18 (+0.17%)

  • 02
    Mar
ABBV AbbVie
$109.14 /

+0.18 (+0.17%)

ALKS Alkermes
$32.12 /

+0.26 (+0.82%)

ABBV AbbVie
$109.14 /

+0.18 (+0.17%)

ABBV AbbVie
$109.14 /

+0.18 (+0.17%)

Conference/Events
Jefferies specialty pharma analyst to hold analyst/industry conference call » 10:36
10/15/21
10/15
10:36
10/15/21
10:36
ABBV

AbbVie

$109.75 /

+0.79 (+0.73%)

, ITCI

Intra-Cellular

$39.84 /

+0.49 (+1.25%)

, ALKS

Alkermes

$32.15 /

+0.29 (+0.91%)

, KRTX

Karuna Therapeutics

$123.10 /

+0.425 (+0.35%)

, OTSKY

Otsuka

$21.31 /

+0.155 (+0.73%)

Specialty Pharma &…

Specialty Pharma & Healthcare Services Analyst Vane-Tempest, along with Dr. Robert Feder a psychiatrist in private practice in Manchester, NH, discuss antipsychotics on an Analyst/Industry conference call to be held on October 15 at 12 pm.

ShowHide Related Items >><<
OTSKY Otsuka
$21.31 /

+0.155 (+0.73%)

KRTX Karuna Therapeutics
$123.10 /

+0.425 (+0.35%)

ITCI Intra-Cellular
$39.84 /

+0.49 (+1.25%)

ALKS Alkermes
$32.15 /

+0.29 (+0.91%)

ABBV AbbVie
$109.75 /

+0.79 (+0.73%)

ABBV AbbVie
$109.75 /

+0.79 (+0.73%)

10/05/21 Piper Sandler
Biohaven Pharmaceutical price target raised to $156 from $140 at Piper Sandler
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/14/21 Barclays
Regenxbio price target raised to $82 from $79 at Barclays
09/13/21 Chardan
Regenxbio pact with AbbVie accelerates RGX-314 'value capture,' says Chardan
ITCI Intra-Cellular
$39.84 /

+0.49 (+1.25%)

09/22/21 Needham
Intra-Cellular initiated with a Buy at Needham
09/20/21 Jefferies
Intra-Cellular price target raised to $70 from $55 at Jefferies
12/29/20 Cantor Fitzgerald
Intra-Cellular price target raised to $54 from $53 at Cantor Fitzgerald
12/15/20
Fly Intel: Top five analyst initiations
ALKS Alkermes
$32.15 /

+0.29 (+0.91%)

10/06/21 Jefferies
Alkermes upgraded to Buy from Hold at Jefferies
09/27/21 BofA
Alkermes takeover thesis 'highly speculative,' says BofA
09/10/21 Mizuho
Alkermes price target raised to $36 from $33 at Mizuho
09/02/21
Fly Intel: Top five analyst downgrades
KRTX Karuna Therapeutics
$123.10 /

+0.425 (+0.35%)

09/30/21 JPMorgan
Karuna Therapeutics initiated with an Overweight at JPMorgan
08/30/21 Citi
Karuna Therapeutics initiated with a Buy at Citi
07/28/21
Fly Intel: Top five analyst initiations
07/28/21 Jefferies
Karuna Therapeutics initiated with a Buy at Jefferies
OTSKY Otsuka
$21.31 /

+0.155 (+0.73%)

07/14/21 Goldman Sachs
Otsuka downgraded to Sell from Neutral at Goldman Sachs
06/17/21 Daiwa
Otsuka upgraded to Outperform from Neutral at Daiwa
03/15/21 Daiwa
Otsuka downgraded to Neutral from Outperform at Daiwa
KRTX Karuna Therapeutics
$123.10 /

+0.425 (+0.35%)

ITCI Intra-Cellular
$39.84 /

+0.49 (+1.25%)

ALKS Alkermes
$32.15 /

+0.29 (+0.91%)

ABBV AbbVie
$109.75 /

+0.79 (+0.73%)

  • 02
    Mar
ABBV AbbVie
$109.75 /

+0.79 (+0.73%)

ALKS Alkermes
$32.15 /

+0.29 (+0.91%)

ABBV AbbVie
$109.75 /

+0.79 (+0.73%)

ABBV AbbVie
$109.75 /

+0.79 (+0.73%)

Conference/Events
Intra-Cellular to hold a virtual investor event » 17:24
10/11/21
10/11
17:24
10/11/21
17:24
ITCI

Intra-Cellular

$37.55 /

-0.39 (-1.03%)

Virtual Event to feature…

Virtual Event to feature highlights of several of the Company's development pipeline including lumateperone, ITI-1284, PDE inhibitor platform and ITI-333 will be held on October 20 at 12:30 pm. Webcast Link

ShowHide Related Items >><<
ITCI Intra-Cellular
$37.55 /

-0.39 (-1.03%)

ITCI Intra-Cellular
$37.55 /

-0.39 (-1.03%)

09/22/21 Needham
Intra-Cellular initiated with a Buy at Needham
09/20/21 Jefferies
Intra-Cellular price target raised to $70 from $55 at Jefferies
12/29/20 Cantor Fitzgerald
Intra-Cellular price target raised to $54 from $53 at Cantor Fitzgerald
12/15/20
Fly Intel: Top five analyst initiations
ITCI Intra-Cellular
$37.55 /

-0.39 (-1.03%)

Hot Stocks
Intra-Cellular announces publication of Phase 3 study of lumateperone » 07:34
09/27/21
09/27
07:34
09/27/21
07:34
ITCI

Intra-Cellular

$36.78 /

-1.16 (-3.06%)

Intra-Cellular Therapies…

Intra-Cellular Therapies announced the publication of the results from its lumateperone monotherapy Phase 3 clinical trial. The article, "Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial," was published online in The American Journal of Psychiatry and is available here. "We are excited about the robust results seen across our bipolar depression program. The study reported on today, Study 404, our monotherapy study, along with Study 402, our adjunctive study with lithium or valproate form the basis of our supplemental NDAs under FDA review. If approved, we plan to to launch immediately and look forward to bringing CAPLYTA to market for the treatment of bipolar depression," said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. Study 404 assesed the efficacy and safety of lumateperone as monotherapy in patients with bipolar I or bipolar II disorder experiencing a major depressive episode. This global study randomized 381 patients with moderate to severe depression symptoms to receive placebo or lumateperone 42 mg for 6 weeks. The primary endpoint was the efficacy of 42 mg/day of lumateperone compared with placebo, measured by mean change from baseline to day 43 in Montgomery-Asberg Depression Rating Scale Total Score. In this clinical trial, treatment with lumateperone resulted in a substantial reduction in depressive symptoms. lumateperone 42mg was associated with a statically significant greater reduction in MADRS score from baseline to day 43. Lumateperone 42 mg significantly improved MADRS Total Score compared with placebo as early as week 1, the first time point measured, with continuing improvement throughout the study. Additionally, significant improvement in MADRS Total Score in the lumateperone group compared with placebo group at Day 43 was observed both in patients with bipolar I disorder and in those with bipolar II disorder. Improvements were also seen in important secondary endpoints. Lumateperone 42 mg met the key secondary endpoint of statistically significant improvement on the CGI-BP-S Total Score and on the CGI component that specifically assesses depression. Results support the favorable safety and tolerability profile of lumateperone. The most commonly reported adverse events occurring for lumateperone 42mg in greater than5% of patients and twice the rate in the placebo group were somnolence and nausea.

ShowHide Related Items >><<
ITCI Intra-Cellular
$36.78 /

-1.16 (-3.06%)

ITCI Intra-Cellular
$36.78 /

-1.16 (-3.06%)

09/22/21 Needham
Intra-Cellular initiated with a Buy at Needham
09/20/21 Jefferies
Intra-Cellular price target raised to $70 from $55 at Jefferies
12/29/20 Cantor Fitzgerald
Intra-Cellular price target raised to $54 from $53 at Cantor Fitzgerald
12/15/20
Fly Intel: Top five analyst initiations
ITCI Intra-Cellular
$36.78 /

-1.16 (-3.06%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.